Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...